These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 2774511)

  • 21. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
    Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
    Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.
    Nutt JG; Woodward WR; Anderson JL
    Ann Neurol; 1985 Nov; 18(5):537-43. PubMed ID: 4073849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Subcutaneous apomorphine--a valuable therapeutic alternative in Parkinson disease].
    Odin P; Mangalanayagam L; Nilsson B; Lindvall O
    Lakartidningen; 1991 Nov; 88(45):3811-4. PubMed ID: 1943399
    [No Abstract]   [Full Text] [Related]  

  • 31. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans.
    Angst MS; Dyck JB; Azarnoff DL; Goldblum R; Ho B; Gfroerer T; Linton EA; Glynn BP; Shafer SL
    Clin Pharmacol Ther; 1998 Nov; 64(5):499-510. PubMed ID: 9834042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease].
    Miranda M; Saéz D
    Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
    Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
    J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 40. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.